^
    Back
    Association details:
    Biomarker:HER-2 positive + APC mutation
    Cancer:Gastric Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ESMO 2023
    Title:

    1561P - APC mutation (mt.), MYC, and GATA6 amplifications (amp.) were associated with worse survival in HER2-positive advanced gastric cancer patients treated with S-1/capecitabine plus oxaliplatin combined with trastuzumab (T-mab) and nivolumab (N-mab)

    Published date:
    10/16/2023
    Excerpt:
    Patients were treated with S-1 80 mg/m2/day or Capecitabine 2000 mg/m2/day on days 1-14 with oxaliplatin 130 mg/m2, N-mab 360mg, and T-mab 8mg/kg for initial treatment, and subsequently with 6 mg/kg on day 1, repeated every 3 weeks....Patients with APC mut. showed significantly shorter PFS (median 5.6 vs 20.8 months, HR 3.47, 95%CI 1.16-10.44, p = 0.018)…
    Secondary therapy:
    oxaliplatin + gimeracil/oteracil/tegafur; capecitabine + oxaliplatin